Direct PeptidesProduct page includes use or preparation wordingIn stock
Elamipretide (SS-31) · 10 mg × 10 vials
$619.00$6.19 / mg
Checked · 5 days ago
Lab report: Not linked
View product details (opens in a new tab)No commercial relationship
Research listings · Peptides
Elamipretide (SS-31) research listings: prices and suppliers
Research materials and consumer products belong to different categories. A listing, laboratory report, or research-use label does not establish suitability for personal use.
We have no commercial relationship with suppliers on this page. Offers are sorted by price per mg; commission never changes the order.
Prices observed weekly · last check · How we check prices →
Lowest current at 10 mg × 10 vials$6.19 / mg · $619.00Direct Peptides · checked 5 days ago
Listings at 10 mg × 10 vials
| Supplier link | |||||||
|---|---|---|---|---|---|---|---|
| Direct PeptidesProduct page includes use or preparation wording | 10 mg × 10 vials | $619.00 | $6.19 / mg | In stock | 5 d ago | Not linked | View product details (opens in a new tab)No commercial relationship |
- Prices exclude shipping. A matching name does not verify the contents of a lot.
- Lab reports are vendor-reported, not independently authenticated. “Lab confirmed” means the issuing laboratory confirmed the report is theirs.
- Some suppliers’ product pages include use or preparation wording. We list their prices for comparison only; we do not endorse that wording, and nothing on this site is guidance on preparing or using these materials.
By size
Every package size we track for Elamipretide (SS-31). Current means seen in the last 8 days.
| 5 mg × 1 vial | $41.95 | $8.39 / mg | 1 / 1 | 1 |
|---|---|---|---|---|
| 10 mg × 1 vial | $39.99 | $4.00 / mg | 8 / 8 | 7 |
| 30 mg × 1 vial | $160.00 | $5.33 / mg | 1 / 1 | 1 |
| 50 mg × 1 vial | $174.00 | $3.48 / mg | 2 / 3 | 2 |
| 10 mg × 10 vials | $619.00 | $6.19 / mg | 1 / 1 | 1 |
Research context
From our own records, with the date each was last checked.
- FDA approval
- Approved: Forzinity (elamipretide hydrochloride), NDA 215244, accelerated approval on 2025-09-19Checked
- 503A / 503B compounding
- Not in any 503A category on FDA's 2026-05-14 listChecked
- Advisory committee (PCAC)
- No PCAC meeting on elamipretide found on FDA's 2022 to 2027 PCAC meeting pages (checked 2026-11-03)Checked
- Rulemaking / enforcement
- No proposed or final rule found (search on 2026-11-03); FDA matches are a 2024 advisory committee meeting notice and a 2025-12-19 priority review voucher notice for ForzinityChecked
- Identity
- Formula C32H49N9O5 · MW 639.8 g/mol · CAS 736992-21-5Sequence D-Arg-Dmt-Lys-Phe-NH2 (Dmt = 2,6-dimethyl-L-tyrosine)Source record Checked
Identity noteResearch listings are not Forzinity. They are not FDA-approved medicines and are not made or checked by the company that makes Forzinity, which contains the hydrochloride salt.
How we check prices · Offers are matched to our catalogue by an editor before they appear; a listing is not an endorsement.